Skip to Content
Merck
CN

O1385

Ozagrel hydrochloride hydrate

≥98% (HPLC), solid

Synonym(s):

(E)-3-[4-(Imidazol-1-ylmethyl)phenyl]propenoic acid hydrochloride hydrate, OKY-046

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C13H12N2O2 · HCl · xH2O
CAS Number:
78712-43-3
Molecular Weight:
264.71 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
24897942
UNSPSC Code:
12352200
MDL number:
MFCD00911569

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Ozagrel hydrochloride hydrate, ≥98% (HPLC), solid

InChI

1S/C13H12N2O2.ClH.H2O/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;;/h1-8,10H,9H2,(H,16,17);1H;1H2/b6-5+;;

SMILES string

O.Cl.OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1

InChI key

OWIZTYOMGVTSDP-TXOOBNKBSA-N

assay

≥98% (HPLC)

form

solid

storage condition

desiccated

color

white to off-white

solubility

H2O: soluble

storage temp.

room temp

Quality Level

100

Related Categories

Application

Ozagrel hydrochloride hydrate has been used as a thromboxane synthase inhibitor:
  • in high cholesterol-diet rats (HC) to test its effect on arteriolar constriction
  • to pre-treat mice to test its effect on lipopolysaccharide (LPS)-induced behavioral changes
  • to test its effect on arteriolar vasoconstriction in hyperglycemic mice

Biochem/physiol Actions

Ozagrel is a selective thromboxane A2 synthase (TXA2) inhibitor.
Ozagrel is useful in treating lacunar and thrombotic stroke. It blocks vasoconstriction and platelet aggregation. Ozagrel aids in improving the prostacyclin (PGI2)/ thromboxane A2 (TXA2) in the acute phase of cerebral ischemia. It improves endothelial dysfunction in L-methionine-induced hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID).

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
047K47072
047K47071
047K4707
011K4603

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yoichi Ishitsuka et al.
Journal of pharmacological sciences, 111(2), 211-215 (2009-09-29)
This study examined the effect of ozagrel, a thromboxane A(2) synthase inhibitor, on the accumulation of leucocytes and chemokine mRNA expression in lungs experimentally injured using oleic acid (OA). OA injection into guinea pigs rapidly increased thromboxane A(2) generation and
K Shinagawa et al.
British journal of pharmacology, 131(2), 266-270 (2000-09-19)
1. The purpose of this study was to investigate the involvement of thromboxane A(2) (TXA(2)) in the cough response in a guinea-pig cough model. Here, we describe results obtained using a selective TXA(2) synthetase inhibitor, ozagrel, and a selective TXA(2)
Takayuki Matsumoto et al.
Atherosclerosis, 205(1), 87-95 (2008-12-30)
Thromboxane A(2) (TXA(2)) is thought to contribute to the development of diabetic complications. We tested the hypothesis that the impaired endothelial function seen in Otsuka Long-Evans Tokushima Fatty (OLETF) rats (a type 2 diabetic model) might be improved by chronic
Yukiko Enomoto et al.
Atherosclerosis, 209(2), 415-421 (2009-11-26)
The plasma level of soluble CD40 ligand (sCD40L), which induces pro-inflammatory and pro-atherogenic responses, is known to be elevated in atherosclerotic patients. In this study, we investigated the mechanism of sCD40L release from human platelets, focusing on the involvement of
Sang In Park et al.
Brain research, 1599, 85-92 (2015-01-04)
We investigated the neuroprotective properties of single doses of minocycline and ozagrel when administered prior to stroke. Male Sprague-Dawley rats were assigned randomly to one of the following groups: (1) control (Con) group (n=10), (2) minocycline (Mino) group (n=10), (3)
View All Related Papers

Related Content

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service